louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02682628: 18791 - Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agent
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-02-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor (SPF) efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF
* Signed and dated Informed Consent Form
* Signed and dated HIPAA Form
* An unbmbiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been dianoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma. diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment DArkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02765828: Identification of Tongue Involvement in Late-Onset Pompe Disease
Official title: Determining the Diagnostic Utility of the Identification of Tongue Involvement in Late-Onset Pompe Disease (LOPD)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myopathy
Neuropathy
Glycogen Storage Disease Type II (Late-onset Pompe Disease)
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Genzyme, a Sanofi Company
First posted: 2016-05-09
Enrollment: 73
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Prospective participants must have a confirmed diagnosis of late-onset Pompe Disease, acquired/hereditary myopathy, or neuropathy.

Brief summary: This purpose of this study is to determine if tongue strength and tongue ultrasound measurements differentiates patients with untreated late-onset Pompe Disease (LOPD) from patients with acquires/hereditary myopathies or neuropathies. It is hypothesized that abnormalities in tongue function and structure in patients with LOPD may be useful in discriminating this condition from others that have similar presentations.


Eligibility criteria: Inclusion Criteria:

* age ≥ 12 years
* confirmed diagnosis of LOPD and naïve to enzyme-replacement therapy (ERT)
* acquired/hereditary myopathy (e.g., dermatomyositis, polymyositis, inclusion body myositis, limb-girdle muscular dystrophy, distal myopathy, myotonic muscular dystrophy, and other myopathy)
* neuropathy (e.g., peripheral neuropathy, cranial neuropathy, autonomic neuropathy, focal neuropathy)

Exclusion Criteria:

* current use, history within the past two years of use, or eligible but declined use of Lumizyme® enzyme replacement therapy (applicable to LOPD group)
* history of stroke, Parkinson's disease, oculopharyngeal muscular dystrophy, head and neck cancer or radiation treatment to head/neck, or other conditions that commonly affect lingual strength
* inability to follow directions for study participation

Primary outcomes:
measure: Maximal lingual (tongue) strength measured via manual muscle testing (MMT) measured via ordinal scale (see description)
timeFrame: Day 1
measure: Maximal lingual (tongue) strength measured via quantitative muscle testing (QMT) measured in kilopascals (KPA)
timeFrame: Day 1
Secondary outcomes:
measure: Maximal muscle thickness measured with ultrasound assessment in millimeters (mm)
timeFrame: Day 1
measure: Echo intensity measured with ultrasound assessment utilizing grayscale analysis
timeFrame: Day 1
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Division of Head and Neck Surgery & Communication Sciences, Duke University Medical Center
name: Harrison Jones, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03824028: Post-Market Clinical Survey of Clareon® IOL AutonoMe™ in Japanese Subjects
Official title: Post-Market Clinical Survey of Clareon® IOL With the AutonoMe™ Automated Preloaded Delivery System With Japanese Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cataract
Keywords: Cataract surgery
Intraocular lens
IOL
Clareon
AutonoMe
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2019-01-31
Enrollment: 384
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects will be enrolled at approximately 20 investigative sites located in Japan.

Brief summary: This purpose of this survey study is to collect and describe clinical outcomes for the intraocular lens (IOL) delivery performance of Clareon® IOL AutonoMe™ when used in daily practice.

Detailed description: This study will enroll subjects who underwent prior cataract surgery with phacoemulsification and were implanted with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system. Subjects will be enrolled post-operatively and followed for one year.

Eligibility criteria: Inclusion Criteria:

* Able to comprehend and willing to sign informed consent.
* Prior diagnosis of age-related cataracts.
* Prior cataract surgery with implantation of Clareon IOL in the capsular bag by AutonoMe™.
* No ophthalmic disease which might affect visual acuity.

Exclusion Criteria:

* None.

Primary outcomes:
measure: Best-corrected distance visual acuity
timeFrame: Up to Year 1 postoperative
measure: Intraocular lens (IOL) delivery performance
timeFrame: Surgery day (retrospective)
measure: Difference between target refraction and postoperative subjective refraction (spherical equivalent)
timeFrame: Up to Year 1 postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Yokohama
country: Japan
facility: Alcon Investigative Site
state: Kanagawa
city: Yokkaichi
country: Japan
facility: Alcon Investigative Site
state: Mie
city: Hashimoto
country: Japan
facility: Alcon Investigative Site
state: Wakayama
Study officials:
affiliation: Alcon Japan, Ltd.
name: Alcon Research
role: STUDY_DIRECTOR
References:
citation: Oshika T, Sasaki N; Clinical Study Group on New Intraocular Lens and Delivery System. One-year multicenter evaluation of a new hydrophobic acrylic intraocular lens with hydroxyethyl methacrylate in an automated preloaded delivery system. J Cataract Refract Surg. 2022 Mar 1;48(3):275-279. doi: 10.1097/j.jcrs.0000000000000746.
Clinical trial NCT03701828: Liver Health and Metabolic Function in People With Obesity
Official title: Liver Health and Metabolic Function in People With Obesity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Non-Alcoholic Fatty Liver Disease
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2018-10-10
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.

Detailed description: Non-alcoholic fatty liver disease (NAFLD) affects approximately 70% of those with obesity and if left untreated can progress to cirrhosis and liver failure. NAFLD stages progress from the stage of simple steatosis to steatohepatitis, and fibrosis The stage of NAFLD is currently best determined using histology from a liver biopsy, however this provides a static depiction of the state of the liver. Therefore, this project aims to determine fibrogenesis in the liver of obese humans in vivo, before and after weight loss.

Eligibility criteria: Inclusion Criteria:

* Body mass index ≥35 kg/m2
* Scheduled for Bariatric surgery

Exclusion Criteria:

* Significant organ disfunction/disease
* Tobacco use
* Previous bariatric surgery
* Pregnancy
* Excessive alcohol use
* Liver disease other than NAFLD

Primary outcomes:
measure: Liver histology
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Hepatic Fibrogenesis
timeFrame: Before and after ~20% weightloss, up to 6 months
Secondary outcomes:
measure: Plasma protein synthesis
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Tissue inflammation
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Systemic inflammation
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Body composition
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Adipose histology
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Tissue gene expression
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Tissue lipidomics
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Insulin sensitivity
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: tissue extracellular vesicles
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: adipose tissue progenitor cells
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: Liver single cell RNA seq
timeFrame: at the time of surgery only
measure: Liver flow cytometry
timeFrame: at the time of surgery only
measure: Liver lipid turnover
timeFrame: Before and after ~20% weightloss, up to 6 months
measure: PNPLA3 synthesis
timeFrame: At the time of surgery only
Other outcomes:
measure: PNPLA3 genotype
timeFrame: Screening only
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
References:
Clinical trial NCT07015528: Assessment of Drug Liking In Peri-procedural Clinical Settings
Official title: Assessment of Drug Liking In Peri-procedural Clinical Settings
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: EARLY_PHASE1
Conditions: Drug Liking
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status classification of I, II or III
* Candidates who are expected to receive fentanyl up to 3 mcg/kg IBW for their scheduled for surgery or procedure (for example, endoscopies)

Exclusion Criteria.

* Craniofacial abnormalities
* Known or suspected difficult intubation or mask ventilation
* Known or suspected need for rapid sequence induction and intubation
* Clinically significant pulmonary disease, such as chronic obstructive lung disease requiring long-term oxygen therapy, or other conditions that, in the study team's judgment, may increase the risk of severe respiratory depression with opioid administration
* History of cardiac conduction disorders
* History of psychosis
* History of movement disorders e.g. Parkinson's Disease
* Past chronic use of anti-psychotics
* Current use of levodopa, lithium, clozapine, metoclopramide, benzodiazepines
* Current use of opioids
* History of opiate abuse within the last 3 years
* Known or suspected severe chronic pain condition that require use of opiates or limit daily activities
* History of pheochromocytoma
* History of concomitant prolactin-dependent tumors e.g. prolactinoma, breast cancer
* Pregnancy or nursing
* Failure to satisfy the investigator of fitness to participate for any other reason

Primary outcomes:
measure: Change in Drug Liking Rating
timeFrame: Baseline (pre-intervention), and 1, 3, and 5 minutes following fentanyl administration
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford Hospital
state: California
Study officials:
affiliation: Stanford University
name: Patrick L Purdon, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05191628: Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole
Official title: Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Macular Holes
Retinal Detachment
Lead sponsor: TBF Genie Tissulaire
Sponsor class: INDUSTRY
First posted: 2022-01-13
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this open, multicenter trial is to assess the impact of the use of an amniotic membrane graft on the closure of macular hole-associated retinal detachment in patients with failed previous macular surgery.


Eligibility criteria: Inclusion Criteria:

* Man or woman over 18 years of age, less than 75 years
* Macular Hole of all etiologies
* Patient with history of opened macular hole after previous pars plana vitrectomy
* Delay between previous surgery and inclusion (relapse or non-closing hole) \> 1 month
* Patient who received the study information and provided consent
* Patient who is a members or a beneficiary of a national health insurance plan

Exclusion Criteria:

* Ocular surgery other than the macular hole surgery in the prior 3 months
* Participation in other clinical studies in the prior 3 months
* Any current or prior ocular pathology that could interfere with the conduct of the study, including visually significant cataract or media opacity
* Patient with uncontrolled glaucoma on more than 1 intraocular lowering medication
* Patient with uveitis or other active ocular inflammation or infection
* Pregnant or breast-feeding woman. Women of childbearing age will be asked to undergo a pregnancy test before being enrolled into the study or to use an effective birth control method
* Person deprived of liberty by judicial or administrative measures
* Any other reason which in the opinion of the investigator would preclude the adherence of the schedules visits, safe participation in the study or affect the results of the study

Primary outcomes:
measure: Closure of recurrent macular hole
timeFrame: 6 months
Secondary outcomes:
measure: Absence of adverse reaction
timeFrame: 7 days, 15 days, 1 month, 3 months, 6 months
measure: Functional restoration after closure of the macular hole
timeFrame: 7 days, 15 days, 1 month, 3 months, 6 months
measure: Anatomical restoration
timeFrame: 1 month, 3 months, 6 months
measure: Evaluation of the surgical technique of placing the membrane
timeFrame: 7 days, 15 days, 1 month, 3 months, 6 months
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital de la Croix-Rousse, Hospices Civils de Lyon
Study officials:
References:
Clinical trial NCT05410028: New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence
Official title: New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence Via Analysis of Immunoinflammation-related Protein Complexes in Blood
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ovarian Cancer
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2022-06-08
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Before treatment, after surgery, during chemotherapy, and after chemotherapy, patients with confirmed ovarian epithelial cancer had different time cutoff points until clinically confirmed patients recurred.

Brief summary: In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.

Detailed description: Time cohort study: patients with confirmed ovarian epithelial cancer at different time cutoff points before treatment, after surgery, during chemotherapy, and after chemotherapy, until clinically confirmed patients relapse. At least 50 patients are expected to be enrolled.

Eligibility criteria: Inclusion Criteria:

* Female
* A diagnosed patient with epithelial ovarian cancer
* Age ≤ 70

Exclusion Criteria:

* Male
* Suffering from other malignant tumors
* Non-compliant patient
* Age above 70

Primary outcomes:
measure: Immune Inflammation-Related Protein Complexes
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT02490228: Effectivity and Safety Study of Trans-artificial-urethral Resection of Female Urethral Caruncle
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Urethral Caruncle
Keywords: female
minimally invasive surgery
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
First posted: 2015-07-03
Enrollment: 100
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To explore the minimally invasive and exhaustive treatment of female urethral canruncle by using trans-artificial-urethral resection of the canruncle. The investigators plant to recruit patients using this surgical method and study the effectivity of this method.


Eligibility criteria: Inclusion Criteria:

- patient with urethral caruncle

Exclusion Criteria:

- recurrence urethral caruncle

Primary outcomes:
measure: Operative time
timeFrame: Up to 6 months
measure: Length of hospital stay
timeFrame: Up to 6 months
measure: Estimated blood loss
timeFrame: Up to 6 months
measure: pathological type
timeFrame: Up to 6 months
measure: Complication incidence rate
timeFrame: Up to 6 months
Secondary outcomes:
measure: recurrence-free survival
timeFrame: Up to 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00697528: Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy
Official title: Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Graves' Disease
Graves' Ophthalmopathy
Keywords: Graves
Color Doppler Imaging
Graves' Ophthalmopathy
Orbital Venous Flow
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2008-06-16
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Grave's disease within the orbital service of HCFMUSP at the Ophthalmology Department

Brief summary: Orbital Venous flow study in patients with Grave's Orbitopathy in different manifestation forms and stages, made with Color Doppler Imaging

Detailed description: Prospective study with Grave's patients in active and fibrotic disease, myogenic and lipogenic forms, with muscle restriction and without muscle restriction and with or without optic compressive neuropathy. Blood flow was studied with Color Doppler Imaging (CDI) in the following orbital vessels:

* Superior Ophthalmic Vein (main target of the study protocol)
* Retinal Central Vein
* Retinal Central Artery
* Ophthalmic Artery

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Grave's Orbitopathy with well defined disease.

Exclusion Criteria:

* Uncertain cases, with an undefined status of Grave's Ophthalmopathy.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Hospital das Clínicas da Universidade São Paulo
Study officials:
affiliation: Instituto do Coracao
name: Mário LR Monteiro, Professor
role: STUDY_DIRECTOR
affiliation: Instituto do Coracao
name: Joseph E Benabou
role: STUDY_CHAIR
References:
citation: Monteiro ML, Moritz RB, Angotti Neto H, Benabou JE. Color Doppler imaging of the superior ophthalmic vein in patients with Graves' orbitopathy before and after treatment of congestive disease. Clinics (Sao Paulo). 2011;66(8):1329-34. doi: 10.1590/s1807-59322011000800004.
Clinical trial NCT02760511: Anthocyanin Dose-escalation Study in Healthy Young Adults
Official title: Anthocyanin Dose-escalation Study in Healthy Young Adults: A CONSORT-compliant, Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Randomized Controlled Trial
Anthocyanin
Antioxidants
Lead sponsor: Shaoguan University
Sponsor class: OTHER
Collaborators: name: Sun Yat-sen University
First posted: 2016-05-03
Enrollment: 122
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Anthocyanins are naturally existing, polyphenolic compounds found in the vacuolar sap of the epidermal tissues of flowers and fruits, with a pink, red, blue, or purple color. Recently, study of anthocyanin pigments has drawn more and more interest since several epidemiological studies have demonstrated their health-promoting properties, such as reducing lipid accumulation and decreasing oxidative stress and inflammation. Nevertheless, there is a clear need for advancing understanding with regard to effective amounts of intake for these phytochemicals. The aim of this study was to investigate the efficacy and pharmacokinetics of anthocyanin in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Blood test, liver function test, renal function test are normal;
* Blood lipids, cardiac function are normal;
* 18.5\<BMI\<23.9;
* Regular dietary, seldomly eating outside;
* Stable condition of body weight in recent 3 months

Exclusion Criteria:

* \> 140 grams of alcohol/week for male and \>70 grams of alcohol/week for female, smoking regularly;
* Known diagnosis of acute diseases or chronic diseases in recent 1 month;
* Be planning to be pregnant in a year, or being pregnant and lactation.

Primary outcomes:
measure: Plasma total antioxidant capacity
timeFrame: 2 weeks
measure: Plasma malondialdehyde concentrations
timeFrame: 2 weeks
measure: Plasma 8-iso-prostaglandin concentrations
timeFrame: 2 weeks
Secondary outcomes:
measure: Plasma tumor necrosis factor alpha concentrations
timeFrame: 2 weeks
measure: Plasma interleukin-6 concentrations
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Shaoguan
country: China
facility: Shaoguan University
state: Guangdong
Study officials:
References: